

**Fabio Villa\***

IE Business School, Madrid, Spain

**Dates:** Received: 04 December, 2015; Accepted: 15 December, 2015; **Published:** 17 December, 2015**\*Corresponding author:** Fabio Villa, IE Business School, Madrid, Spain, Tel: +41 (0)91 811 91 76; Fax +41 (0)91 811 91 74; E-mail: fabiovilla210486@gmail.com[www.peertechz.com](http://www.peertechz.com)**ISSN:** 2454-2968**Keywords:** Non-small cell lung cancer; EGFR; Adjuvant; Neoadjuvant; Thoracic surgery**Perspective**

## EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC

**Abstract**

5-year survival rates of Non-Small Cell Lung Cancer (NSCLC) remain unsatisfactory after surgery with curative intent and disease recurrences, including distant metastases, are frequent. Only a minority of this heterogeneous disease is positive for EGFR mutations and suitable for Tyrosine Kinase-Inhibitor biological agents, which however present limits in terms of stable response to treatment, due to the acquired drug resistances. A few trials administrating EGFR inhibitors combined with surgery, in neoadjuvant or adjuvant settings, have been reported with lack of evidence. The third-generation EGFR inhibitors, with the amelioration of techniques of gene profiling and the knowledge of pathways could extent the spectrum of complementary-to-surgery treatments in NSCLC at high risk of relapse.

5-year survival rates of NSCLC remain unsatisfactory after surgery with curative intent and disease recurrences, including distant metastases, are frequent [1]. These findings suggest a common micrometastatic pattern for NSCLC retained amenable for curative resection. Nowadays the guidelines from the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) recommend adjuvant cisplatin-based regimen for patients with completely resected stage II or IIIA NSCLC [2], while neoadjuvant therapy has shown promising results when a good pathological response is observed and negative resection margins are achieved [3]. In these trials neoadjuvant chemotherapy has been performed exclusively by cytotoxic agents. Despite toxicity progression free survival and overall survival are significantly improved by neoadjuvant and adjuvant treatments in stage III NSCLC, although weaker evidences have been found for stage II NSCLC. Nevertheless strategies for the identification of patients who can obtain the best gain from surgery are still lacking. Gene expression profiling has already been used to detect patients at risk of recurrences and candidates to adjuvant treatment [4]. In this study patients with K-ras mutations did not have benefits by the administration of adjuvant therapy, and patients with the overexpression of p53 had better response despite the poorer prognosis. This auspicious approach leads to the personalized treatment of NSCLC and presumably brings the perspective of a revision of the current staging classification based upon macroscopic tools, clearly insufficient.

Within this context remarkable efforts have been made to assess the real prognostic and therapeutic implications of the EGFR mutations in NSCLC.

A number of trials on EGFR inhibitors for neoadjuvant and adjuvant therapy of NSCLC have been developed in the recent years. The rationale is that complementary to surgery biological agents could represent a cancer signaling-targeted strategy to control the disease, including micrometastases overgrowth, hypothesized to be sustained by the crosstalk with the main mass. EGFR inhibitors could reduce continued dissemination of cancer and the 'seed and soil' interaction with macro and microenvironment. EGFR is in fact strongly

involved in lymphatic and hematogenous spread of aberrant cells and in their pro-metastatic interactions with stromal tissue [5]. EGFR mutations play also a role in evasion of tumor immunosurveillance [6]. Molecular-targeted agents could strengthen surgery before and after it, even though it has been observed great inter and intra-individual variability in response in non-surgical patients due to the complexity of mitogenic redundant pathways, the heterogeneity of mutations among cancer populations and the possibility of acquired resistance [7].

In 2009 thirty-six patients have been enrolled in the first phase II study on preoperative Gefitinib in an unselected population [8]. Not surprisingly EGFR mutation was the strongest predictor of response. Schaake et al. [9], report a metabolic response at PET scan (defined as >25% standardized uptake value decrease) in 27% of patients using neoadjuvant Erlotinib, but only 5% of responder at CT evaluation according to the Response Evaluation Criteria in Solid Tumors (RECIST). Patients were substantially unselected for EGFR mutations, despite the study population was enriched with never-smokers, females, nonsquamous histology and Asian ethnicity, more likely to have EGFR mutations [7]. Toxicity was well tolerated and lower in comparison with cytotoxic regimens.

In a case report of 2013 it was observed a preoperative down staging using Gefitinib for an EGFR mutation-positive bronchioloalveolar carcinoma, and a complete radiological response after brain recurrence in the adjuvant setting [10].

Monoclonal antibodies are also used for treatment of advanced-stage EGFR mutation-negative NSCLC, and attempts in terms of inductive systemic chemotherapy have been reported with promising results in unselected patients [11]. Panitumumab, the competitor of Cetuximab, has not been used yet as neoadjuvant or adjuvant strategy for NSCLC.

Adjuvant targeted therapy have been better investigated. Evidences of the effectiveness of EGFR inhibitors after surgery are weak [12-14]. Possible explanations include heterogeneity of the study population and the known biases of selection. In addition long term

results are not available yet. It's licit to consider the augmentation of the risk of relapse caused by mutational acquired resistance in a long-term adjuvant treatment. However the preliminary studies on Third-generation EGFR inhibitors have shown promising results of new EGFR-mutant-selective TKIs compounds (AZD9291 and rociletinib). These molecules directed on Thr790Met, the most common mechanism of EGFR inhibitors acquired resistance, seem to overcome the main limit of the biological agents for NSCLC: the stable response to treatment [15]. For this reason they could be hypothetically used combined with surgery in patients suffering from advanced stages of NSCLC, or eventually early stages NSCLC prone to relapse. The amelioration of techniques of gene profiling and the knowledge of pathways could in fact reveal better predictors of outcome, also for early stages NSCLC.

Other trials are ongoing on neoadjuvant and adjuvant treatment of NSCLC, and regularly presented as abstracts at congresses, however planning of studies is difficult for the relative low prevalence of EGFR mutation-positive patients, especially in western countries, and costs. More efforts in research are required.

## References

1. Osaki T, Oyama T, Gu CD, Yamashita T, So T, et al. (2002) Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer. *J Clin Oncol* 20: 2930-2936.
2. Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, et al. (2007) Cancer Care Ontario, American Society of Clinical Oncology. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIa resectable non small-cell lung cancer guideline. *J Clin Oncol* 25: 5506-5518.
3. Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KMW, et al. (2014) The University of Texas MD Anderson Lung Cancer Collaborative Group. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. *Lancet Oncol* 15: e42-50.
4. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, et al. (2007) Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. *J Clin Oncol* 25: 5240-5247.
5. Sasaki T, Hiroki K, Yamashita Y (2013) The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment. *BioMed Res Int* 2013: ID 546318.
6. Klinke DJ 2nd, Kulkarni YM, Wu Y, Byrne-Hoffman C (2014) Inferring alterations in cell-to-cell communication in HER2+ breast cancer using secretome profiling of three cell models. *Biotechnol Bioeng* 111: 1853-63.
7. Antonicelli A, Cafarotti S, Indini A, Galli A, Russo A, et al. (2013) EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. *Int J Med Sci* 10: 320-330.
8. Lara-Guerra H, Waddell TK, Salvarrey MA, Joshua AM, Chung CT, et al. (2009) Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. *J Clin Oncol* 27: 6229-6236.
9. Schaake EE, Kappers I, Codrington HE, Valdés Olmos RA, Teertstra HJ, et al. (2012) Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. *J Clin Oncol* 30: 2731-2738.
10. López-González A, Almagro E, Salas C, Varela A, Provencio M (2013) Use of a tyrosine kinase inhibitor as neoadjuvant therapy for non-small cell lung cancer: A case report. *Respir Med Case Rep* 9: 8-10.
11. Coate LE, Gately K, Barr MP, Meaney J, O'Connell F, et al. (2006) Phase II pilot study of neoadjuvant cetuximab in combination with cisplatin and gemcitabine in patients with resectable IB-IIIa Non small cell lung cancer. *J Clin Oncol* 24: 17107.
12. Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, et al. (2013) Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. *J Clin Oncol* 31: 3320-3326.
13. D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, et al. (2012) Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. *J Thorac Oncol* 7: 1815-1822.
14. Frances A Shepherd, Nasser K Altorki, Wilfried Ernst Erich Eberhardt, Mary ER O'Brien, David R, et al. (2014) Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial (abstract 7513). *J Clin Oncol* 32: 5s.
15. Tan CS, Gilligan D, Pacey S (2015) Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. *Lancet Oncol* 16: e447-459.